4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Net Margin of 2256.65% for Q1 2026, up 34040050.0% year-over-year from N/an in Q1 2025, and down 9999.37% quarter-over-quarter from 22.8% in Q4 2025.
4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Net Margin data on file, last reported at 2256.65% in Q1 2026.
- Net Margin for Q1 2026 came in at 2256.65%, up 34040050.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 182.34% (up 76694375.0% YoY), and the FY2025 annual result was 164.43%, up 43461395.0% from the prior year.
- Net Margin declined to 2256.65% in Q1 2026 per FDMT's latest filing, from 22.8% in the prior quarter.
- Over five years, Net Margin peaked at 169910.53% in Q4 2023 and troughed at 4967100.0% in Q4 2024.
- A 5-year average of 464398.39% and a median of 12391.63% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin sank 513701053 bps in 2024, then jumped 496712280 bps in 2025.
- A 5-year view of Net Margin shows it stood at 2195.59% in 2022, then jumped by 7839 bps to 169910.53% in 2023, then slumped by 3023 bps to 4967100.0% in 2024, then jumped by 100 bps to 22.8% in 2025, then plunged by 9999 bps to 2256.65% in 2026.
- Business Quant data shows FDMT's Net Margin at 2256.65% in Q1 2026, 22.8% in Q4 2025, and 63195.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -2,256.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,256.65% |
| Dec 31, 2025 | 22.80% |
| Sep 30, 2025 | -63,195.56% |
| Jun 30, 2025 | -364,386.67% |
| Mar 31, 2025 | -342,657.14% |
| Dec 31, 2024 | -4,967,100.00% |
| Sep 30, 2024 | -1,461,433.33% |
| Jun 30, 2024 | -699,060.00% |
| Mar 31, 2024 | -115,717.86% |
| Dec 31, 2023 | 169,910.53% |
| Sep 30, 2023 | -50.76% |
| Jun 30, 2023 | -12,391.63% |
| Mar 31, 2023 | -9,624.83% |
| Dec 31, 2022 | -2,195.59% |
| Sep 30, 2022 | -5,138.20% |
| Jun 30, 2022 | -17,337.04% |
| Mar 31, 2022 | -2,160.62% |
| Dec 31, 2021 | -27,264.13% |
| Sep 30, 2021 | -1,628.04% |
| Jun 30, 2021 | -52.05% |